Immunotherapy, as exemplified by PD-1 inhibitors, have revolutionized the treatment of specific cancer types, often in combination with chemotherapy or targeted therapies. However, a large fraction of patients fails to respond to these treatments. My laboratory is exploring the cancer cell autonomous resistance mechanisms utilizing a combination of techniques such as genetic screening, scRNAseq, and proteomics to study cancer cells that are refractory to T cell mediated killing. Indeed, understanding the resistance mechanism(s) might help the design of future therapeutic strategies for targeting this cell population to produce deeper and longer lasting patient responses.
We work in close collaboration with Dr. Matt Niederst’s lab (Postdoc Co-Mentor) and pharmacology, data sciences, next generation sequencing and translational oncology groups within NIBR as well as external academic collaborators.